# Esperion Therapeutics, Inc. (ESPR) — merger [completed]
Source: SEC API (secapi.ai) · situation sit_be92a3c181a65da1cec2 · retrieved 2026-08-12T21:27:05.697Z

## Overview
Esperion Therapeutics, Inc. is a pharmaceutical company developing treatments for cardiovascular and metabolic diseases.

Esperion Therapeutics stockholders voted on July 8, 2026 to approve the Agreement and Plan of Merger dated May 1, 2026 with Essence Parent Inc. and its wholly owned subsidiary Essence MergerCo Inc. Under the merger agreement, MergerCo will merge with and into Esperion, with Esperion continuing as the surviving corporation and a wholly owned subsidiary of Essence Parent. The vote was approved with 135,326,793 votes in favor, 22,750,628 votes against, and 496,194 abstentions, representing 61.53% of issued and outstanding shares entitled to vote.

## Terms
- Counterparty: Essence Parent Inc.

## Key dates
- Record 2026-05-28 · Vote 2026-07-08 · Completed 2026-07-08

## Timeline
- 2026-07-08 · 8-K (0001104659-26-081588): Esperion stockholders approve merger with Essence Parent; MergerCo to merge into company — *Esperion Therapeutics, Inc. is a pharmaceutical company developing treatments for cardiovascular and metabolic diseases.* Esperion Therapeutics stockholders voted on July 8, 2026 to approve the Agreement and Plan of Merger dated May 1, 2026 with Essence Parent Inc. and its wholly owned subsidiary Essence MergerCo Inc. Under the merger agreement, MergerCo will merge with and into Esperion, with Esperion continuing as the surviving corporation and a wholly owned subsidiary of Essence Parent. The vote was approved with 135,326,793 votes in favor, 22,750,628 votes against, and 496,194 abstentions, representing 61.53% of issued and outstanding shares entitled to vote.
  https://www.sec.gov/Archives/edgar/data/1434868/0001104659-26-081588.txt

## Citations
- 0001104659-26-081588 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465926081588